Man Group
STRO icon

Man Group’s Sutro Biopharma STRO Stock Holding History

Man Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,241
Closed -$244K – 2361
2024
Q4 		$244K Sell
13,241
-3,152
-19% -$96.2K ﹤0.01% 1835
2024
Q3 		$567K Buy
16,393
+3,365
+26% +$132K ﹤0.01% 1638
2024
Q2 		$382K Sell
13,028
-6,035
-32% -$239K ﹤0.01% 1745
2024
Q1 		$1.08M Buy
19,063
+7,154
+60% +$316K ﹤0.01% 1517
2023
Q4 		$511K Buy
+11,909
New +$378K ﹤0.01% 1671
2023
Q3 		– Sell
-24,867
Closed -$1.08M – 1606
2023
Q2 		$1.16M Buy
+24,867
New +$1.24M ﹤0.01% 1349
2023
Q1 		– Sell
-21,644
Closed -$1.37M – 1320
2022
Q4 		$1.75M Buy
21,644
+4,926
+29% +$342K 0.01% 1153
2022
Q3 		$928K Buy
+16,718
New +$989K ﹤0.01% 1313
2022
Q2 		– Sell
-4,250
Closed -$237K – 1377
2022
Q1 		$349K Buy
+4,250
New +$404K ﹤0.01% 1701

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Man Group's STRO Position: Q1 2025 in Review

Man Group sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 13,241 shares — an estimated $244K sold.

Man Group first reported a position in STRO in Q1 2022 and held it in 9 quarters. The position peaked at $1.75M in Q4 2022. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Man Group reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 13,241 Sutro Biopharma shares in Q1 2025, an estimated $244K.
  • Man Group first reported a position in Sutro Biopharma in Q1 2022 and held it in 9 quarters.
  • Man Group's Sutro Biopharma position peaked at $1.75M in Q4 2022.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.